Innate Pharma SA announced that Mondher Mahjoubi has resigned from his position as Chief Executive Officer (CEO) and Chairman of the Executive Board of the Company, effective as of January 2024, to pursue a senior level opportunity at a large pharmaceutical company. Hervé Brailly, Innate Pharma?s current Chairman of the Supervisory Board, former CEO and co-founder is appointed as interim CEO and Chairman of the Executive Board while a permanent successor is sought.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.245 EUR | +2.98% | +6.40% | -14.31% |
Apr. 15 | Sanofi: progress in hematology trial | CF |
Apr. 15 | Innate Pharma: progress in hematology trial | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.31% | 194M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IPH Stock
- News Innate Pharma
- Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024